［1］Peleg AY,Seifert H,Paterson DL.Acinetobacter baumannii: emergence of a successful pathogen［J］.Clin Microbiol Rev，2008，21(3):538-582.
［2］Durante-Mangoni E,Zarrilli R.Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance［J］.Future Microbiol，2011，6(4):407-422.
［3］Lemos EV,de la Hoz FP, Einarson TR,et al.Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis［J］.Clin Microbiol Infect，2014，20(5):416-423.
［4］Landman D,Georgescu C,Martin DA,et al.Polymyxins revisited［J］.Clin Microbiol Rev，2008，21(3):449-465.
［5］Ziaka M,Markantonis SL,Fousteri M,et al.Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection［J］.Antimicrob Agents Chemother，2013，57(4):1938-1940.
［6］Zavascki AP, Goldani LZ, Li J,et al.Polimixin B for the treatment of multidrug-resistant pathogens: a critical review［J］.J Antimicrob Chemother，2007，60(6):1206-1215.
［7］Assamali Z,Jain R,Danziger LH.An update on the arsenal for multidrug-resistant Acinetobacter infections :polymyxin antibiotics［J］.Int J Infect Dis,2015，30 :125-132.
［8］Quintanilha JCF,Duarte NDC,Lloret GR,et al.Colistin and polymyxin B for treatment of nosocomial infections in intensive care unit patients: pharmacoeconomic analysis［J］.Int J Clin Pharm，2019，41(1):74-80.
［9］Aggarwal R,Dewan A.Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study［J］.Ak Ann Clin Microbiol Antimicrob，2018，17(1):15.
［10］Yoon J,Urban C,Terzina C, et al.In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii［J］. Antimicrob Agents Chemother，2004，48(3)：753-757.
［11］Tripodi M-F,Durante-Mangoni E,Fortunato R,et al.Comparative activities of colistin, rifampicin, imipenem, sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases［J］.Int J Antimicrob Agents，2007，30(6)：537-540.
［12］Zusman O,Avni T,Leibovici L,et al.Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems［J］.Antimicrob Agents Chemother，2013，57(10)：5104-5111.
［13］O'Hara JA,Ambe LA,Casella LG,et al.Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains［J］.Antimicrob Agents Chemother，2013，57(5)：2103-2108.
［14］Paul M,Daikos GL,Durante-Mangoni E,et al.Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial［J］.Lancet Infect Dis，2018，18(4):391-400.
［15］Chung ES,Ko KS.Eradication of persister cells of Acinetobacter baumannii through combination of colistin and amikacin antibiotics［J］.J Antimicrob Chemother，2019,74(5):1277-1283.
［16］Altun S,Kocak TZ,Altun B,et al.Growing OXA-23 type strains among carbapenem-resistant Acinetobacter baumannii and tigecycline as an alternate combination therapy［J］.Turk J Med Sci，2016，6(6):1894-1899．
［17］Sun JR,Chan MC,Chang TY,et al.Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS［J］.Antimicrob Agents Chemother，2010，4(11):4934-4938．
［18］Freire AT,Melnyk V,Kim MJ,et al.Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia［J］.Diagn Microbiol Infect Dis，2010，68(2):140-151.
［19］Liang CA,Lin YC,Lu PL,et al.Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii［J］.Clin Microbiol Infect，2018，24(8):908.e1-908.e7.
［20］Ni W,Han Y,Zhao J,et al.Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis［J］.Int J Antimicrob Agents，2016，47(2):107-116.
［21］Ramirez J,Dartois N,Gandjini H,et al.Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia［J］.Antimicrob Agents Chemother，2013，57(4):1756-1762.
［22］Fernández-Cuenca F,Martínez-Martínez L,Conejo MC,et al.Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii［J］.J Antimicrob Chemother，2003，51(3):565-574.
［23］Krizova L,Poirel L,Nordmann P,et al.TEM-1β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii［J］. J Antimicrob Chemother，2013，68(12):2786-2791.
［24］Housman ST,Hagihara M,Nicolau DP,et al.In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam,doripenem and tigecycline alone and incombination against multidrug-resistant Acinetobacter baumannii［J］.J Antimicrob Chemother，2013，68(10):2296-2304.
［25］Jaruratanasirikul S,Wongpoowarak W,Aeinlang N,et al.Pharmacodynamics modeling to optimize dosage regimens of sulbactam［J］.Antimicrob Agents Chemother，2013，57(7):3441-3444.
［26］Betrosian AP,Frantzeskaki F,Xanthaki A,et al.Efficacy and safety of high-dose ampicillin/sulbactam vs.colistinas monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia［J］.J Infect，2008，56(6):432-436.
［27］Khawcharoenporn T,Pruetpongpun N,Tiamsak P,et al.Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia ［J］.Int J Antimicrob Agents，2014，43(4):378-382.
［28］Pachon-Ibanez ME,Docobo-Perez F,Lopez-Rojas L,et al.Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii［J］.Antimicrob Agents Chemother，2010，54(3)：1165-1172.
［29］Nordqvist H,Nilsson LE,Claesson C.Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii［J］.Eur J Clin Microbiol Infect Dis，2016，35(11):1845-1850.
［30］AL-Shaer M,Nazer LH,Kherallah M.Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii［J］.Ann Pharmacother，2014，48(6):766-771.
［31］Mohammadi M,Khayat H,Sayehmiri K,et al.Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii:A systematic review and meta-analysis［J］.Open Microbiol J，2017，11:63-71.
［32］Giannouli M,Di Popolo A,Durante-Mangoni E,et al.Molecular epidemiology and mechanisms of rifampicin resistance in Acinetobacter baumannii isolates from Italy［J］.Int J Antimicrob Agents，2012，39(1):58-63.
［33］Pachon-Ibanez ME, Docobo-Perez F,Lopez-Rojas L,et al.Efficacy of rifampin and its combinations with imipenem,sulbactam,and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii［J］.Antimicrob Agents Chemother，2010，54(3)：1165-1172.
［34］Durante-Mangoni E,Signoriello G,Andini R,et al.Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter,randomized clinical trial［J］.Clin Infect Dis，2013，57(3):349-358.
［35］Santimaleeworagun W,Wongpoowarak P,Chayakul P,et al.In vitro activity of colistin or sulbactam in combination with fosfomycin orimipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases［J］.Southeast Asian J Trop Med Public Health，2011，42(4)：890-900.
［36］Sirijatuphat R,Thamlikitkul V.Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections［J］.Antimicrob Agents Chemother，2014，58(9):5598-5601．
［37］Menegucci TC,Albiero J,Migliorini LB,et al.Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections［J］.Int J Antimicrob Agents，2016，47(5)：380-385.
［38］Shinohara DR, Menegucci TC, Fedrigo NH,et al.Synergistic activity of polymyxin B combined with vancomycin against carbapenem-resistant and polymyxin-resistant Acinetobacter baumannii: first in vitro study［J］.J Med Microbiol，2019，68(3):309-315.
［39］Wareham DW, Gordon NC, Hornsey M.In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii［J］.J Antimicrob Chemother，2011，66(5), 1047-1051.
［40］Hornsey M,Longshaw C,Phee L,et al.In vitro activity of telavancin in combination with colistin versus Gramnegative bacterial pathogens［J］.Antimicrob Agents Chemother，2012，56(6)：3080-3085.
［41］Phee L,Hornsey M,Wareham DW.In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens［J］.Eur J Clin Microbiol Infect Dis,2013,32(10):1291-1294.
［42］Hornsey M,Phee L,Longshaw C,In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection［J］.Int J Antimicrob Agents,2013,41(3):285-287.
［43］Ceccarelli G,Oliva A, d'Ettorre G,et al.The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit［J］.BMC Infect Dis, 2015,30:15:393.
［44］acho-Montero J, Amaya-Villar R,Gutiérrez-Pizarraya A, et al.Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii ［J］.Chemotherapy,2013,59(3):225-231.
［45］Jacobs MR,Abdelhamed AM,Good CE,et al.Activity of Cefiderocol(S-649266), a Siderophore cephalosporin, against gram-negative bacteria, including carbapenem-resistant nonfermenters and entero bacteriaceae with defined extended-spectrum β-lactamases and carbapenemases［J］.Antimicrob Agents Chemother,2018,21,63(1):pii: e01801-18.
［46］Hackel MA, Tsuji M, Yamano Y, et al.In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gramnegative bacilli collected worldwide in 2014-2016［J］.Antimicrob Agents Chemother,2018,62(2):pii:e01968-1017.
［47］Hackel MA,Tsuji M,Yamano Y,et al.In vitro activity of the siderophore cephalosporin,cefiderocol,against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem non-susceptible isolates: the SIDERO-WT-2014 study［J］. Antimicrob Agents Chemother,2017,61(9):pii:e00093-17.
［48］Dobias J,Dénervaud-Tendon V,Poirel L,et al.Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens［J］.Eur J Clin Microbiol Infect Dis,2017,36(12):2319-2327.
［49］Ito A,Sato T,Ota M,et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalo-sporin, against Gram-negative bacteria［J］.Antimicrob Agents Chemother,2017,62(1).pii:e01454-517.
［50］Contreras DA, Fitzwater SP, Nanayakkara DD, et al. Co-infections of two strains of NDM-1 and OXA-232 co-producing Klebsiella pneumoniae in a kidney transplant patient［J］. Antimicrob Agents Chemother, 2019, Sep 16. pii: AAC.00948-19. doi: 10.1128/AAC.00948-19.
［51］Dobias J, Dénervaud-Tendon V, Poirel L,et al.Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens［J］.Eur J Clin Microbiol Infect Dis,2017,36(12):2319-2327.
［52］Ito A,Kohira N,Bouchillon SK, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria［J］.J Antimicrob Chemother,2016,71(3):670-677.
［53］Kazmierczak KM,Tsuji M,Wise MG,et al.In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)［J］. Int J Antimicrob Agents,2019,53(2):177-184.
［54］Portsmouth S,Van Veenhuyzen D,Echols R,et al.Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial［J］.Lancet Infect Dis,2018,18(12):1319-1328.
［55］Zhanel GG,Cheung D,Adam H, et al.Review of eravacycline,a novel fluorocycline antibacterial agent［J］.Drugs,2016,76(5):567-588.
［56］Seifert H,Stefanik D,Sutcliffe JA,et al.In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii［J］.Int J Antimicrob Agents,2018,51(1):62-64.
［57］Zhanel GG,Baxter MR,Adam HJ,et al.In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015［J］.Diagn Microbiol Infect Dis,2018,91(1):55-62.
［58］Livermore DM, Mushtaq S,Warner M,et al.In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii［J］.Antimicrob Agents Chemother,201,60(6):3840-3844.
［59］Abdallah M,Olafisoye O,Cortes C,et al.Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City［J］.Antimicrob Agents Chemother,2015,59(3):1802-1805.
［60］Solomkin JS,Ramesh MK,Cesnauskas G,et al. Phase 2,randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections［J］.Antimicrob Agents Chemother,2014,58(4):1847-1854.
［61］Rodvold KA,Gotfried MH,Isaacs RD,et al.Plasma and Intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects［J］.Antimicrob Agents Chemother,2018,62(11).pii: e01089-18.
［62］Durand-Réville TF,Guler S,Comita-Prevoir J,et al.ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacterbaumannii［J］.Nat Microbiol,2017,2:17104.